Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis

Area of Science:

• Cardiology
• Health Economics
• Pharmacotherapy

Background:

• Combination pharmacotherapy (aspirin, beta-blockers, ACE inhibitors, statins) significantly reduces cardiac events.
• These essential therapies are underutilized, with out-of-pocket costs being a major barrier to patient adherence.
• Underutilization is prevalent even in insured populations post-myocardial infarction (MI).

Purpose of the Study:

• To estimate the economic and clinical impact of providing combination pharmacotherapy without cost sharing to insured patients following an MI.
• To evaluate the effect of full coverage on mortality and reinfarction rates.
• To determine the cost-effectiveness of removing financial barriers to essential post-MI medications.

Main Methods:

• Economic modeling was used to compare outcomes under standard coverage versus full coverage (no cost sharing).
• The analysis focused on insured patients after experiencing a myocardial infarction (MI).
• Outcomes assessed included mortality, reinfarction rates, and healthcare costs over a three-year period.

Main Results:

• Full coverage of combination pharmacotherapy is projected to reduce mortality and reinfarction rates.
• Compared to standard coverage, three years of full coverage is estimated to save $5,974 per patient.
• The findings indicate significant clinical benefits and cost savings associated with eliminating patient cost sharing.

Conclusions:

• Eliminating out-of-pocket spending for combination pharmacotherapy post-MI can improve patient outcomes.
• Providing full coverage for these essential medications is a cost-saving strategy for the healthcare system.
• Policy interventions to ensure affordable access to combination therapy after MI are warranted to save lives and reduce expenditure.